ArticleBMC chemistry2026
New aspirin-chitosan conjugates as potential anti-Staphylococcus aureus agents.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two novel aspirin-chitosan conjugates were successfully designed and synthesized: A phenyl acetate derivative (PAD)/chitosan conjugate and an acetoxybenzoate derivative (ABD)/chitosan conjugate. The conjugates were prepared via freeze-drying methodology, where chitosan was reacted with the phenyl acetate derivative (PAD) 3a and the acetoxybenzoate derivative (ABD) 3b through nucleophilic attack of chitosan's amino groups on the carbonyl carbons of the aspirin-containing derivatives, forming stable amide linkages. The resulting conjugates were comprehensively characterized using infrared spectroscopy (IR), scanning electron microscopy (SEM), and X-ray diffraction (XRD) to confirm successful conjugation and evaluate structural properties. Antibacterial activity was assessed against methicillin-resistant Staphylococcus aureus (MRSA) using colony-forming unit (CFU) assays. Results demonstrated that the Cs/3a conjugate exhibited superior antibacterial efficacy, achieving a significant reduction in S. aureus growth compared to other formulations. These findings suggest that aspirin-chitosan conjugation represents a promising strategy for developing antimicrobial biomaterials with enhanced therapeutic potential against drug-resistant bacterial pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.